XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Analyst Ratings
NASDAQ:XERS - Nasdaq - US98422E1038 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 85% to XERS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.2. This target is 38.72% above the current price.
XERS was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about XERS.
In the previous month the buy percentage consensus was at a similar level.
XERS was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-11 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-11-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-10 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-03-28 | Oppenheimer | Initiate | Outperform |
| 2024-03-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-10 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-28 | Craig-Hallum | Initiate | Buy |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-09 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-27 | SVB Leerink | Maintains | Outperform |
| 2022-04-28 | Craig-Hallum | Initiate | Buy |
| 2022-02-16 | SVB Leerink | Maintains | Outperform |
| 2021-12-31 | SVB Leerink | Maintains | Outperform |
| 2021-12-31 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-17 | SVB Leerink | Initiate | Outperform |
| 2021-10-29 | HC Wainwright & Co. | Initiate | Buy |